Tuesday, September 16, 2025 9/16/2025

Ultra-long Acting Transcutaneously Refillable Islatravir Nanofluidic Implant for HIV Pre-Exposure

Award Number: R01AI165372
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2022
PERIOD OF PERFORMANCE END DATE: 05/31/2027

Group Awards By:

View Award Description

Ultra-long Acting Transcutaneously Refillable Islatravir Nanofluidic Implant for HIV Pre-Exposure - Modified Project Summary/Abstract Section Long-acting (LA) pre-exposure prophylactic (PrEP) strategies offer the promise of improving adherence to therapeutic regimen for maximal HIV preventive efficacy. To this end, we have developed an ultra-long acting antiretroviral (ARV) delivery implant with an unprecedented release duration of at least 2 years uninterrupted for durable and safe HIV prevention independent of user adherence. The NanoDDI is a refillable subcutaneous nanofluidic implant for constant drug release, which comprises a newly patented nanofluidic membrane, and ports for rapid, minimally invasive transcutaneous drug refilling. Refilling is performed manually via a syringe without any complex pumps or equipment to extend implant use duration beyond 2 years. The nanofluidic membrane use nanochannels to control drug release through passive diffusion without pumping mechanisms, permitting discrete, long-term user-independent dosing. Unlike injectables or other LA polymeric strategies, NanoDDI avoids burst and decay release. Zero-order release kinetics is achieved independent of physiological conditions, regardless of interindividual heterogeneity. Importantly, the NanoDDI addresses user preferences for discretion and longer dose duration. The NanoDDI development was originally planned for use with islatravir (ISL), an ARV developed by Merck. However, ISL clinical development for long-acting HIV PrEP was recently terminated by Merck based on lymphocyte depletion concerns, rendering ISL of limited clinical relevance for PrEP. Thus, we have shifted our NanoDDI focus to the potent ARVs, MK8527 (MK) and lenacapavir (LEN). Here we will test the hypothesis that constant and sustained MK8527 (MK) or lenacapavir (LEN) delivery from NanoDDI will achieve preventative drug levels for a 2-year duration and effectively prevent SHIV infection in non-human primates (NHP). This proposal outlines a comprehensive preclinical framework fundamental for developing NanoDDI as a HIV PrEP platform. We aim 1) to develop and optimize NanoDDI and MK and LEN formulations for sustained and constant release in vitro and in rats; 2) to assess pharmacokinetics (PK), tolerability, and safety of NanoDDI-MK85 and NanoDDI-LEN for 2 years in NHP and evaluate effectiveness of transcutaneous drug refilling; and 3) to comprehensively evaluate PrEP efficacy of NanoDDI-MK in NHPs using the vaginal and rectal routes of simian HIV transmission, in dose de-escalation studies. Our multidisciplinary team has a solid history of collaborative HIV PrEP studies with long-acting drug delivery implants. We will use a milestone-driven research approach to advance the NanoDDI technology towards the ultimate goal of clinical translation.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,801,942 )
2025	2025	METHODIST HOSPITAL, THE	6670 BERTNER AVE	HOUSTON	TX	77030	HARRIS	USA	Allergy and Infectious Diseases Research	001	4	8/5/2025	EXTENSION WITH OR WITHOUT FUNDS	$1,801,942
2025	2024	METHODIST HOSPITAL, THE	6670 BERTNER AVE	HOUSTON	TX	77030	HARRIS	USA	Allergy and Infectious Diseases Research	000	3	8/5/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,801,942

Issue Date FY: 2024 ( Subtotal = $948,687 )
2024	2024	METHODIST HOSPITAL, THE	6670 BERTNER AVE	HOUSTON	TX	77030	HARRIS	USA	Allergy and Infectious Diseases Research	001	3	6/27/2024	NON-COMPETING CONTINUATION	$948,687
2024	2023	METHODIST HOSPITAL, THE	6670 BERTNER AVE	HOUSTON	TX	77030	HARRIS	USA	Allergy and Infectious Diseases Research	000	2	11/14/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $948,687

Issue Date FY: 2023 ( Subtotal = $900,458 )
2023	2023	METHODIST HOSPITAL, THE	6670 BERTNER AVE	HOUSTON	TX	77030	HARRIS	USA	Allergy and Infectious Diseases Research	000	2	5/16/2023	NON-COMPETING CONTINUATION	$900,458
														Subtotal = $900,458

Issue Date FY: 2022 ( Subtotal = $808,087 )
2022	2022	METHODIST HOSPITAL, THE	6670 BERTNER AVE	HOUSTON	TX	77030	HARRIS	USA	Allergy and Infectious Diseases Research	000	1	4/7/2022	NEW	$808,087
														Subtotal = $808,087

Grand Total All Awards = $4,459,174

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Ultra-long Acting Transcutaneously Refillable Islatravir Nanofluidic Implant for HIV Pre-Exposure

Award Number: R01AI165372

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2022

PERIOD OF PERFORMANCE END DATE: 05/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer